{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 1,
    "new_evidence_found": 0,
    "total_evidence": 1
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM",
      "relevance_explanation": "This quote identifies Flublok Quadrivalent as a recombinant influenza vaccine with a higher antigen content (45 \u00b5g/0.5 mL) compared to standard-dose egg-based vaccines, which typically contain 15 \u00b5g/0.5 mL. This supports the claim by establishing that a higher-dose recombinant option exists for vaccination."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}